New drug combo aims to slow ALS in landmark trial
Disease control
Recruiting now
This study tests an experimental drug called COYA 302 in 120 adults with ALS. The treatment combines two substances to calm the immune system and reduce nerve damage. Participants will receive either the drug or a placebo for 24 weeks, and may continue on the drug for another 24 …
Phase: PHASE2 • Sponsor: Coya Therapeutics • Aim: Disease control
Last updated May 15, 2026 11:57 UTC